Nisa Investment Advisors LLC Has $5.34 Million Stake in DaVita Inc. (NYSE:DVA)

Nisa Investment Advisors LLC boosted its position in DaVita Inc. (NYSE:DVA - Free Report) by 27.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 50,981 shares of the company's stock after purchasing an additional 11,097 shares during the period. Nisa Investment Advisors LLC owned about 0.06% of DaVita worth $5,341,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Norges Bank acquired a new stake in shares of DaVita during the 4th quarter valued at approximately $116,373,000. Deutsche Bank AG lifted its position in shares of DaVita by 421.8% during the 3rd quarter. Deutsche Bank AG now owns 1,095,081 shares of the company's stock valued at $103,518,000 after acquiring an additional 885,195 shares during the period. Amundi lifted its position in shares of DaVita by 226.3% during the 4th quarter. Amundi now owns 659,372 shares of the company's stock valued at $52,592,000 after acquiring an additional 457,285 shares during the period. Morgan Stanley lifted its position in shares of DaVita by 37.9% during the 4th quarter. Morgan Stanley now owns 1,232,647 shares of the company's stock valued at $92,042,000 after acquiring an additional 339,051 shares during the period. Finally, Point72 Asset Management L.P. lifted its position in shares of DaVita by 912.4% during the 4th quarter. Point72 Asset Management L.P. now owns 338,139 shares of the company's stock valued at $25,249,000 after acquiring an additional 304,739 shares during the period. Institutional investors and hedge funds own 90.12% of the company's stock.

Insiders Place Their Bets

In other DaVita news, CEO Javier Rodriguez sold 67,603 shares of DaVita stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $126.11, for a total value of $8,525,414.33. Following the completion of the sale, the chief executive officer now directly owns 488,697 shares of the company's stock, valued at approximately $61,629,578.67. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CEO Javier Rodriguez sold 67,603 shares of the business's stock in a transaction on Monday, February 26th. The shares were sold at an average price of $126.11, for a total transaction of $8,525,414.33. Following the completion of the sale, the chief executive officer now directly owns 488,697 shares of the company's stock, valued at approximately $61,629,578.67. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider James O. Hearty sold 26,164 shares of the business's stock in a transaction on Friday, February 16th. The shares were sold at an average price of $119.64, for a total transaction of $3,130,260.96. Following the sale, the insider now directly owns 20,264 shares of the company's stock, valued at $2,424,384.96. The disclosure for this sale can be found here. In the last three months, insiders sold 134,540 shares of company stock valued at $16,551,071. Company insiders own 1.40% of the company's stock.

Wall Street Analyst Weigh In

DVA has been the subject of a number of research reports. StockNews.com upgraded shares of DaVita from a "buy" rating to a "strong-buy" rating in a research report on Monday. TheStreet raised shares of DaVita from a "c+" rating to a "b-" rating in a research note on Wednesday, February 7th. Barclays began coverage on shares of DaVita in a research note on Wednesday, March 6th. They set an "equal weight" rating and a $133.00 price objective for the company. Truist Financial raised their price objective on shares of DaVita from $130.00 to $135.00 and gave the stock a "hold" rating in a research note on Tuesday, February 20th. Finally, UBS Group raised their price objective on shares of DaVita from $113.00 to $134.00 and gave the stock a "buy" rating in a research note on Wednesday, February 14th. Two investment analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, DaVita presently has a consensus rating of "Moderate Buy" and an average price target of $118.50.

DaVita Trading Down 0.5 %

DVA stock traded down $0.66 during midday trading on Thursday, hitting $131.40. The stock had a trading volume of 342,087 shares, compared to its average volume of 843,401. The firm has a market cap of $11.52 billion, a PE ratio of 17.76, a price-to-earnings-growth ratio of 1.19 and a beta of 1.04. The company has a debt-to-equity ratio of 6.65, a current ratio of 1.19 and a quick ratio of 1.13. DaVita Inc. has a 12-month low of $71.51 and a 12-month high of $141.54. The company's 50-day moving average price is $128.57 and its 200 day moving average price is $107.66.

DaVita (NYSE:DVA - Get Free Report) last released its earnings results on Tuesday, February 13th. The company reported $1.87 EPS for the quarter, topping the consensus estimate of $1.53 by $0.34. The firm had revenue of $3.15 billion during the quarter, compared to analysts' expectations of $3.01 billion. DaVita had a net margin of 5.70% and a return on equity of 64.42%. DaVita's revenue for the quarter was up 7.8% on a year-over-year basis. During the same period in the previous year, the company earned $1.11 EPS. On average, equities research analysts predict that DaVita Inc. will post 9.23 earnings per share for the current fiscal year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.